Edwards commission: weak rx for ailing u. S. Fda

Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this

journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now

Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer

support Authors * B.J. Spalding View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE

THIS ARTICLE Spalding, B. Edwards Commission: Weak Rx for Ailing U.S. FDA. _Nat Biotechnol_ 9, 539–540 (1991). https://doi.org/10.1038/nbt0691-539 Download citation * Issue Date: 01 June

1991 * DOI: https://doi.org/10.1038/nbt0691-539 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is

not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative